RxDoctor Payments Data

Renee Lamm, MD

Addiction Psychiatry · Myrtle Beach, SCNPI 1245214592

Payments from drug & device makers

$1,266,798in general payments, 2019–2025

Across 2,150 payments — averaging $589.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$419K
  • Axsome Therapeutics, Inc.$306K
  • AbbVie$201K
  • Teva Pharmaceuticals USA, Inc.$176K
  • Alkermes, Inc.$107K
  • Vanda Pharmaceuticals Inc.$18K
  • plus $40K from 24 others

What the payments were for

  • Consulting fees$175,50814%
  • Speaking & faculty fees$967,42976%
  • Travel & lodging$91,3797%
  • Food & beverage$32,3363%
  • Education$1470%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few addiction psychiatry providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$107,977
Medicare patients
176
Services billed
1,130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine56$339,370
IngrezzaValbenazine Tosylate30$243,283
TrintellixVortioxetine Hydrobromide106$81,072
RexultiBrexpiprazole28$39,347
Invega SustennaPaliperidone Palmitate11$36,921
AuvelityDextromethorphan Hbr/Bupropion33$33,126
Lurasidone Hcl50$29,273
VraylarCariprazine Hcl19$27,108
VyvanseLisdexamfetamine Dimesylate33$14,882
NamzaricMemantine Hcl/Donepezil Hcl19$11,117
Duloxetine Hcl208$8,876
Paliperidone ErPaliperidone11$7,151
Lisdexamfetamine Dimesylate30$6,201
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl35$5,428
FetzimaLevomilnacipran Hcl12$5,346

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr$175,814$339,37056 claims
Neurocrine Biosciences, Inc.Ingrezza$9,965$243,28330 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$7,713$95,954139 claims
AbbVieVraylar, Namzaric, Fetzima$200,722$43,57150 claims
Otsuka America Pharmaceutical, Inc.Rexulti$419,498$39,34728 claims
Johnson & JohnsonInvega Sustenna$10,481$36,92111 claims
Axsome Therapeutics, Inc.Auvelity$305,850$33,12633 claims
Lilly USA, LLCOlanzapine$15$2,41681 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction psychiatry providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other addiction psychiatry in Myrtle Beach

Where these figures come from

Is this you, or does something look wrong? →